 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12345678910111213...858859» |
- MODULE 4: Selection and Sequencing of Therapy for Relapsed/Refractory HCC (San Francisco Marriott Marquis, Golden Gate Ballroom ) - Dec 19, 2024 - Abstract #ASCOGI2025ASCO_GI_994;
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, and Merck. Effect of patient- and disease-related factors, validated biomarkers and prior exposure and response to treatment on clinical decision-making for advanced HCC that has progressed on first and consecutive lines of therapy Role of approved first-line multitargeted TKIs, such as sorafenib and lenvatinib, among patients with relapsed disease Long-term outcomes with approved anti-angiogenic agents, such as regorafenib, cabozantinib and ramucirumab, for patients with progressive HCC Key findings with anti-PD-1/PD-L1 antibody-based strategies for progressive HCC; role, if any, for patients who have experienced disease progression on first-line immunotherapeutic approaches Other novel agents and strategies under investigation for patients with advanced HCC
- || Review, Journal, Metastases: Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. (Pubmed Central) - Dec 18, 2024
In this Review, we provide a comprehensive overview of advances in the field over the past few years and offer a practical perspective on translation of the most relevant results into the daily management of patients with metastatic colorectal cancer using an evidence-based algorithm. Finally, we discuss some of the most appealing ongoing areas of research and highlight approaches with the potential to further expand the therapeutic armamentarium.
- || pemvidutide (ALT-801) / Altimmune
Clinical, Journal: Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. (Pubmed Central) - Dec 18, 2024
P1
Finally, we discuss some of the most appealing ongoing areas of research and highlight approaches with the potential to further expand the therapeutic armamentarium. In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo.
- || Review, Journal: New onset heart failure in adolescents with inflammatory joint disease treated with TNF-? inhibitors: a case-based review. (Pubmed Central) - Dec 18, 2024
A thorough literature search revealed that these are the only cases of heart failure reported to date after anti-TNF treatment in adolescents with rheumatic diseases. Although cardiovascular adverse effects seem to be very rare in this population, even atypical symptoms of cardiac failure should not be ignored, and cardiac function should be closely monitored when administering anti-TNF-?.
- | Blincyto (blinatumomab) / Astellas, Amgen
Retrospective data, Journal: Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study. (Pubmed Central) - Dec 18, 2024
Although cardiovascular adverse effects seem to be very rare in this population, even atypical symptoms of cardiac failure should not be ignored, and cardiac function should be closely monitored when administering anti-TNF-?. Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost-efficiency and resource management in health care.
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Dec 18, 2024
P1, N=188, Recruiting, Sponsor: Amgen
Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost-efficiency and resource management in health care. Trial completion date: Apr 2028 --> Feb 2029 | Trial primary completion date: May 2026 --> Feb 2027
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New P3 trial: Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma (clinicaltrials.gov) - Dec 18, 2024
P3, N=10, Not yet recruiting, Sponsor: Dr. Andrew Thamboo, MD
- ||| Revuforj (revumenib) / Syndax Pharma
Enrollment closed, Enrollment change: Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=42, Active, not recruiting, Sponsor: Syndax Pharmaceuticals
Trial completion date: Apr 2028 --> Feb 2029 | Trial primary completion date: May 2026 --> Feb 2027 Recruiting --> Active, not recruiting | N=158 --> 42
- | New P2 trial, Real-world evidence, Pan tumor, Real-world: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (clinicaltrials.gov) - Dec 18, 2024
P2, N=300, Recruiting, Sponsor: Tianjin Medical University Second Hospital
- | Repatha (evolocumab) / Amgen, Astellas
New trial: EVEREST: Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: a Target Trial Emulation (clinicaltrials.gov) - Dec 18, 2024
P=N/A, N=912, Active, not recruiting, Sponsor: Shanghai Zhongshan Hospital
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Does evolocumab treatment reduce carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia? (Pubmed Central) - Dec 18, 2024
Recruiting --> Active, not recruiting | N=158 --> 42 No abstract available
- |||| Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: COLONGER: An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (clinicaltrials.gov) - Dec 18, 2024
P=N/A, N=2326, Active, not recruiting, Sponsor: Bayer
No abstract available Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
- || Repatha (evolocumab) / Amgen, Astellas
Biomarker, P2 data, Journal, PARP Biomarker, Metastases: Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy. (Pubmed Central) - Dec 18, 2024
P2
This study is approved by the Human Research Ethics Committee (X22-0072 and 2022/ETH00427). It is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12622001003763).
- | SB202190 / Amgen
Preclinical, Journal: In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-? signaling pathway in human hair follicle stem cells and dermal papilla cells. (Pubmed Central) - Dec 18, 2024
signaling pathway in human hair follicle cells. Therefore, araliadiol can be considered a novel drug candidate for the treatment of alopecia.
- | Venclexta (venetoclax) / Roche, AbbVie, Xpovio (selinexor) / Karyopharm
Trial completion date, Combination therapy: SELCLAX: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 18, 2024
P1, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
Therefore, araliadiol can be considered a novel drug candidate for the treatment of alopecia. Trial completion date: Jul 2025 --> Jun 2027
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal, Claims database: Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database. (Pubmed Central) - Dec 18, 2024
Trial completion date: Jul 2025 --> Jun 2027 The estimated incidence and prevalence rates of TED demonstrate the considerable impact of this disease in the United States, making the creation of a specific ICD code imperative for effective healthcare planning and management.
- | Rituxan (rituximab) / Roche
Journal: Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report (Pubmed Central) - Dec 18, 2024
For the patient in this study, MG symptoms improved with increased dosage of prednisone...In conclusion, RA combined with MG is rare. For patients exhibiting poor responses to csDMARDs, low-dose, long-interval rituximab might be a promising treatment option.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL. (Pubmed Central) - Dec 18, 2024
For patients exhibiting poor responses to csDMARDs, low-dose, long-interval rituximab might be a promising treatment option. No abstract available
- | certepetide (LSTA1) / Lisata Therap, Vectibix (panitumumab) / Amgen
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=50, Active, not recruiting, Sponsor: Anup Kasi
No abstract available Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
- | Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen
Journal: Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. (Pubmed Central) - Dec 17, 2024
In conclusion, the simultaneous combination of ponatinib and blinatumomab is a highly effective and relatively safe nonchemotherapy regimen. This regimen also reduces the need for intensive chemotherapy and HSCT in first remission in the majority of patients.
- ||| Tepezza (teprotumumab-trbw) / Roche, Amgen
P4 data, Journal, Adverse events, Real-world evidence, Real-world: Post-marketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment. (Pubmed Central) - Dec 17, 2024
Clinicians and pharmacists should be vigilant regarding these AEs. However, available data are currently insufficient, and further pharmacovigilance and surveillance are needed to fully understand this issue.
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Journal, Metastases: Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. (Pubmed Central) - Dec 17, 2024
Palbociclib at standard dose may offer superior outcomes. These findings support personalized dosing strategies to optimize efficacy and tolerability in frail or elderly patients.
- | Journal, IO biomarker: Management of Hypercholesterolemia in Patients with Coronary Artery Disease: A Glimpse into the Future. (Pubmed Central) - Dec 17, 2024
The aim of this review is to present the landscape of therapies already approved to reduce LDL-C levels, evaluating their efficacy, tolerability, and indications. Moreover, we take a glimpse into the future to evaluate experimental novel therapies to lower LDL-C levels that will be approved in the next few years or are under clinical evaluation.
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Surgical Management of Adult Spinal Deformity Patients with Osteoporosis. (Pubmed Central) - Dec 17, 2024
Specifically, expandable screws and cement augmentation have been shown to improve fixation stability. However, further research is needed to evaluate the effectiveness of these treatments, specifically in osteoporotic ASD patients.
- AlloStim (bioengineered allogeneic immune cells) / Immunovative
A phase 2, multicenter, open-label study of AlloStim combined with anti-PD-L1 immunotherapy as 4L therapy in patients with MSS/pMMR metastatic colorectal cancer. (Level 1, West Hall; Poster Bd #: M26) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_974;
P2
The study is a phase 2, multicenter, single-arm clinical trial of MSS/pMMR mCRC subjects in 4L that have been previously treated with an oxaliplatin-containing and irinotecan-containing chemotherapy regimen, anti-EGFR (RAS wt and left-sided), anti-VEGF and have progressed on 3L TAS-102 +/- bevacizumab or regorafenib or fruquinitinib...CT scans are conducted at baseline, day 56 after AlloStim priming, day 112 after combination of alternating q2w infusions of AlloStim and avelumab and day 168 in all patients...Up to 50 patients will be enrolled with an interim analysis performed to assess efficacy after 20 patients become evaluable. The study is open and has not yet enrolled any patients at time of submission.
- becotarug (JMT101) / CSPC Pharma
A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC). (Level 1, West Hall; Poster Bd #: M22) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_970;
P2
Eligible patients are histologically confirmed mCRC without MSI-H/dMMR, wild-type RAS and BRAF, who progressed on at least 2 prior systemic therapy with chemotherapy based on 5-FU with oxaliplatin and irinotecan, with or without cetuximab and bevacizumab (both parts); no prior treatment with regorafenib, fruquintinib, or TAS-102 (part II)...Secondary endpoints include JMT101 and SG001 pharmacokinetic profile, antidrug antibodies (ADA) (both parts), disease control rate (DCR), duration of response (DOR), progression free survival (PFS), and overall survival (OS), as well as safety (part II). Prespecified goal for safety run-in part was met; randomized treatment part accrual began in February 2024.
- Keytruda (pembrolizumab) / Merck (MSD), Stivarga (regorafenib) / Bayer
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01. (Level 1, West Hall; Poster Bd #: M21) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_969;
P2
For the lead-in phase of the study, the emphasis is on controlling Type I error to be small, approximately 0.05. The test statistic will be the number of ORRs in the 22 patients, which we assume to follow a binomial distribution.
- Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C (Level 1, West Hall; Poster Bd #: N8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_961;
P1, P3
The test statistic will be the number of ORRs in the 22 patients, which we assume to follow a binomial distribution. Clinical Trial Registration Number: NCT06252649 Background: CodeBreaK 300 (NCT05198934) evaluated sotorasib, a selective inhibitor that irreversibly binds to the Kirsten rat sarcoma (KRAS) G12C mutant protein, in combination with panitumumab, an anti
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Clinical and molecular characterization of FAP and SPP1 in colorectal cancer (CRC), CALGB (Alliance)/SWOG 80405 and real-world data. (Level 1, West Hall; Poster Bd #: L10) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_936;
P3
Additionally, their expression may be prognostic and predictive of targeted therapy. These data support the evaluation of FAP and SPP1 as predictive markers and therapeutic targets in CRC.
- Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study. (Level 1, West Hall; Poster Bd #: K8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_933;
P3
At final analysis, co-formulated fave/pembro did not improve OS vs SOC in pts with PD-L1-positive MSS/pMMR mCRC. The safety profile was manageable with no new safety signals observed.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
Association between ctDNA levels, timing of blood collection, and overall survival in metastatic colorectal cancer. (Level 1, West Hall; Poster Bd #: K5) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_930;
Patients with ctDNA levels <10 showed significantly better OS across all treatment lines. Optimal timing of blood collection can enhance ctDNA levels, enabling more accurate gene mutation assessment and stratifying outcomes.
- Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis
Phase II study of cabozantinib and nivolumab in refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC). (Level 1, West Hall; Poster Bd #: J15) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_887;
P2
Most patients (84%) had not received prior trifluridine/tipiracil; only 1 patient had received prior regorafenib... The combination of cabozantinib and nivolumab was well tolerated and provided modest benefit in a population of patients with metastatic, chemotherapy refractory, MSS CRC.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer. (Level 1, West Hall; Poster Bd #: H6) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_874;
P2/3
Anlotinib showed promising efficacy and a favorable safety profile as a later-line treatment for advanced colorectal cancer. These findings suggest that anlotinib may be a viable clinical option for advanced CRC, though larger-scale clinical trials are necessary to confirm these results and further define its role in treatment.
- QL1203 / Qilu Pharma
QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial. (Level 1, West Hall; Poster Bd #: H2) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_866;
P3
Funded by No funding sources reported Clinical Trial Registration Number: NCT04233151 Background: Panitumumab plus FOLFOX or FOLFIRI has been approved as the first-line therapy for RAS wild-type mCRC... QL1203 demonstrated significantly improved PFS versus placebo and higher ORR.
- Fruzaqla (fruquintinib) / Takeda
Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. (Level 1, West Hall; Poster Bd #: G9) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_855;
P3
Furthermore, these analyses are robust with consistent results reported using IPCW and MSM. These findings support fruquintinib as a new treatment option for patients with previously treated mCRC.
- Vectibix (panitumumab) / Amgen, Cabometyx (cabozantinib tablet) / Exelixis
Phase I/II study of cabozantinib alone or in combination with panitumumab in patients with MET-amplified metastatic colorectal cancer. (Level 1, West Hall; Poster Bd #: F7) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_829;
P1/2
However, this treatment did not demonstrate significant clinical benefit in patients with MET-amplified mCRC. Further investigation is warranted to explore alternative therapeutic strategies for this patient population.
- Fruzaqla (fruquintinib) / Takeda
Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ?10 months in the FRESCO-2 study. (Level 1, West Hall; Poster Bd #: F3) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_826;
P3
The data show a higher proportion of pts with OS ?10 mos had an absence of liver mets and ECOG PS 0 at BL than the ITT pop. The safety profile of F in pts with OS ?10 mos was consistent with the ITT pop.
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. (Level 1, West Hall; Poster Bd #: F21) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_822;
(PARADIGM, FIRE-3, CALGB 80405 and the PEAK). This phenomenon also explains the crossover of the survival curves in PARADIGM study and the benefits of bevacizumab obtained preferentially in patients with short survival (rt.
- Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Adverse events (AEs) (Level 1, West Hall; Poster Bd #: E18) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_802;
P1
Moreover, it discovered that integration of AE-derived biomarkers with molecular biomarkers could produce a more robust classifier than when considered individually. This analysis is the first of its kind to identify subgroups of CRC patients that benefit from IC treatment.
- zanzalintinib (XL092) / Exelixis
Zanzalintinib (XL092) alone or in combination with atezolizumab in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results from an expansion cohort of the phase 1 STELLAR-001 study. (Level 1, West Hall; Poster Bd #: E13) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_797;
P1, P3
Greater activity was seen with zanza+atezo versus zanza alone, particularly in pts without LM. Both treatments were generally well tolerated.
- Erbitux (cetuximab) / Eli Lilly
A protocol for pretreatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions. (Level 1, West Hall; Poster Bd #: E2) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_782;
A testing threshold of 0.1 kUA/L is effective in identifying patients at risk. Implementing this protocol can improve the safety of cetuximab therapy in high-risk populations.
- Stivarga (regorafenib) / Bayer, Tafinlar (dabrafenib) / Novartis
Integrating pharmacogenetic testing in the management of gastrointestinal cancers. (Level 1, West Hall; Poster Bd #: D25) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_780;
These findings highlight the therapeutic significance of incorporating genetic testing into clinical practice to tailor treatments, enhance drug efficacy, and minimize side effects in GI cancer management. By integrating pharmacogenetic insights, the safety and effectiveness of therapies can be significantly improved, ultimately leading to better patient care in GI oncology.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Nationwide analysis of Medicare expenditure and utilization of EGFR inhibitors from 2018-2022. (Level 1, West Hall; Poster Bd #: D24) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_779;
As we move away from chemotherapy and shift our focus to targeted therapies, it is imperative to explore generic alternatives and direct policy changes to ensure equitable access across various racial and socio-economic groups. These findings highlight the need for further research into healthcare policy reforms to ease the burden on our health system.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Disparities in prophylactic tetracycline use among patients with metastatic colorectal cancer undergoing treatment with EGFR inhibitors. (Level 1, West Hall; Poster Bd #: D21) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_776;
Disparities in cancer care are also evidenced by lower use of tetracyclines in elderly and African Americans. Randomized controlled trials support the use of prophylactic tetracycline in these patients; thus, further research into the reason for this practice gap is necessary.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
Survival outcomes for right- versus left-sided colon cancer and rectal cancer in patients receiving regorafenib and/or trifluridine/tipiracil for refractory metastatic colorectal cancer: Findings from the multicenter retrospective ReTrITa study. (Level 1, West Hall; Poster Bd #: C4) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_746;
Examining the pts groups treated with R and T as monotherapy based on the primary tumour site, however, did not allow us to make any significant conclusions. Treatment decisions should, however, constantly include the patient's characteristics, such as sex, ECOG PS, and the extent of metastatic disease.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI + bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC). (Level 1, West Hall; Poster Bd #: C18) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_737;
This is the first study to compare the clinical outcomes with FTD-TPI vs. FTD-TPI+bev in Black pts with mCRC in the real-world setting. Our study confirmed OS improvement with FTD-TPI+bev as compared to FTD-TPI in Black pts with mCRC, as seen in the overall population of the SUNLIGHT trial.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Real-world clinical outcomes of patients (Pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI + bevacizumab (FTD-TPI+bev) combination therapy. (Level 1, West Hall; Poster Bd #: C16) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_735;
FTD-TPI+bev improved clinical outcomes including rwOS, rwTTD, and rwTTNTD, as compared to FTD-TPI in pts with mCRC. These findings align with the results of the SUNLIGHT trial.
- Lonsurf (trifluridine/tipiracil) / Otsuka
Comparative efficacy of TAS-102 and chemotherapy rechallenge in the third-line setting and beyond in patients with advanced colorectal cancer: A retrospective study. (Level 1, West Hall; Poster Bd #: C15) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_734;
Options include Trifluridine/Tipiracil (TAS-102), TAS-102 with bevacizumab, regorafenib, chemotherapy rechallenge with or without an anti-EGFR agent, or fruquintinib...Among the chemotherapy rechallenge group, 31% were treated with cetuximab and 6% had panitumumab rechallenge, some of which were guided by cell free DNA liquid biopsy testing... Patients with metastatic colorectal cancer who received chemotherapy rechallenge in the third line setting survived longer compared with patients who received TAS-102 with or without bevacizumab, or regorafenib.
- A real-world study of treatment patterns among patients (pts) with metastatic colorectal cancer (mCRC) receiving third-line (3L) or fourth-line (4L) treatment in the US. (Level 1, West Hall; Poster Bd #: C1) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_728;
Characterization of treatment patterns in US pts from 1/2018 to 3/2023 showed that standard CT +/- targeted therapy was used frequently in 3L and 4L, demonstrating an unmet need for additional therapies. Approval of novel treatments, such as fruquintinib, may help to address this need.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Real-world (RW) treatment patterns and clinical outcomes of patients treated with sequential regorafenib and trifluridine/tipiracil (Level 1, West Hall; Poster Bd #: B25) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_726;
The one-year median duration of survival in this real-world setting confirms the importance of access to these treatments in patients with mCRC and can inform physicians regarding the choice of medications while sequencing therapies in mCRC. Clinical outcomes among R-T and T-R mCRC patients.1 Entire R-T and T-R cohorts are presented since 16 patients in each cohort initiated T+BEV.